ArticleOphthalmology science2026
An Ensemble Learning Artificial Intelligence Model for Alzheimer's Disease Detection Using OCT.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: There has been significant progress in detecting Alzheimer's disease (AD) using retinal imaging. We developed an ensemble learning-based deep learning (DL) model, integrating different inputs from OCT for the detection of AD-dementia and early AD. Design: A retrospective multicenter case-control study. Participants: A total of 190 participants with AD-dementia and 623 cognitively normal controls were recruited from 2 cohorts in Hong Kong and Singapore as the training and internal validation sets. A total of 46 participants with AD-dementia, 79 participants with mild cognitive impairment (MCI), and 52 cognitively normal controls from 2 cohorts with amyloid-β status identified from positron emission tomography (PET) available in Hong Kong and Singapore as External-1 and External-2, respectively. Methods: We developed DL models for identifying AD-dementia versus cognitively normal and also tested the proposed ensemble model for classifying MCI (symptom-based) and AD-MCI (PET-based). Inputs were generated from a commercially available OCT device (Cirrus HD-OCT, Carl Zeiss Meditec, Inc), including optic nerve head (ONH)-centered and macula-centered Main Outcome Measures: Discriminative performance of the ensemble model for detecting AD-dementia, MCI, and AD-MCI. Results: For detecting AD-dementia, the ensemble model achieved the area under the receiver operating characteristic curve (AUROC) of 0.943 (95% confidence interval, 0.906-0.980), 0.786 (95% confidence interval, 0.673-0.899), and 0.795 (95% confidence interval, 0.716-0.874) in the internal validation, External-1, and External-2, respectively. For detecting AD-MCI defined by PET biomarkers, the ensemble model achieved AUROCs of 0.787 (95% confidence interval, 0.643-0.931) and 0.791 (95% confidence interval, 0.694-0.888) in the External-1 and External-2, respectively. Conclusions: Our proposed ensemble model, integrating multiple base models and inputs from OCT analysis, demonstrates strong potential for leveraging OCT imaging in detecting both AD-dementia and early-stage AD, enabling opportunistic screening for AD during ophthalmic visits. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.